Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

NCT05565014 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Effusion
Malignant Peritoneal Effusion

Interventions

DRUG: Virus Activated Killer immune Cells
DRUG: Saline

Sponsor

Sheng Hu

Collaborators

[object Object]